Clinical trial
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (SESAD)
NCT04902703 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (SESAD)
- Lead sponsor
- University of Colorado, Denver
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 1, 2022
- Completion date
- November 30, 2026
- Enrollment
- 42 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.